GliclazideCAS# 21187-98-4 |
- Mycophenolate Mofetil
Catalog No.:BCC2290
CAS No.:128794-94-5
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
- Trilostane
Catalog No.:BCC2302
CAS No.:13647-35-3
- AGI-6780
Catalog No.:BCC1331
CAS No.:1432660-47-3
- CPI-613
Catalog No.:BCC2287
CAS No.:95809-78-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 21187-98-4 | SDF | Download SDF |
| PubChem ID | 3475 | Appearance | Powder |
| Formula | C15H21N3O3S | M.Wt | 323.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (309.21 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea | ||
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2 | ||
| Standard InChIKey | BOVGTQGAOIONJV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Gliclazide Dilution Calculator
Gliclazide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0921 mL | 15.4603 mL | 30.9205 mL | 61.841 mL | 77.3013 mL |
| 5 mM | 0.6184 mL | 3.0921 mL | 6.1841 mL | 12.3682 mL | 15.4603 mL |
| 10 mM | 0.3092 mL | 1.546 mL | 3.0921 mL | 6.1841 mL | 7.7301 mL |
| 50 mM | 0.0618 mL | 0.3092 mL | 0.6184 mL | 1.2368 mL | 1.546 mL |
| 100 mM | 0.0309 mL | 0.1546 mL | 0.3092 mL | 0.6184 mL | 0.773 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Gliclazide is a sulfonylurea hypoglycemic agent used as an antidiabetic.
- Flumorph
Catalog No.:BCC5467
CAS No.:211867-47-9
- Nudicaucin A
Catalog No.:BCN7842
CAS No.:211815-97-3
- 2',4',5'-Trimethoxy-2'',2''-dimethylpyrano[5'',6'':6,7]isoflavone
Catalog No.:BCN1496
CAS No.:211799-56-3
- Picroside IV
Catalog No.:BCN6533
CAS No.:211567-04-3
- Nudicaucin B
Catalog No.:BCN7843
CAS No.:211557-36-7
- WHI-P180
Catalog No.:BCC3928
CAS No.:211555-08-7
- WHI-P97
Catalog No.:BCC2056
CAS No.:211555-05-4
- WHI-P154
Catalog No.:BCC2202
CAS No.:211555-04-3
- Dalcetrapib (JTT-705, RO4607381)
Catalog No.:BCC2328
CAS No.:211513-37-0
- Dendrobine
Catalog No.:BCN5923
CAS No.:2115-91-5
- Astrocasine
Catalog No.:BCN2150
CAS No.:2114-92-3
- R18
Catalog No.:BCC2383
CAS No.:211364-78-2
- BIBR 953 (Dabigatran, Pradaxa)
Catalog No.:BCC2139
CAS No.:211914-51-1
- BIBR-1048
Catalog No.:BCC3738
CAS No.:211915-06-9
- 1,3,7-Trihydroxy-2-methoxyxanthone
Catalog No.:BCN7549
CAS No.:211948-69-5
- Vatalanib (PTK787) 2HCl
Catalog No.:BCC1111
CAS No.:212141-51-0
- Vatalanib
Catalog No.:BCC2085
CAS No.:212141-54-3
- Apparicine
Catalog No.:BCN4008
CAS No.:2122-36-3
- 5,7-Dihydroxy-3-(4-hydroxy-3,5-dimethoxybenzyl)-6,8-dimethylchroman-4-one
Catalog No.:BCN6631
CAS No.:212201-12-2
- Ipfencarbazone
Catalog No.:BCC5465
CAS No.:212201-70-2
- Ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate
Catalog No.:BCC8971
CAS No.:212322-56-0
- TC 2559 difumarate
Catalog No.:BCC7469
CAS No.:212332-35-9
- HS 024
Catalog No.:BCC5820
CAS No.:212370-59-7
- Oxaprozin
Catalog No.:BCC9109
CAS No.:21256-18-8
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.[Pubmed:28332301]
J Diabetes. 2017 Aug;9(8):800-809.
BACKGROUND: The aim of the present study was to compare the effects of Gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). METHODS: Eighty-seven subjects were randomized to receive liraglutide, metformin, or Gliclazide for 24 weeks. Primary outcomes included HbA1c levels, intrahepatic fat (IHF) content, and liver function. RESULTS: Both HbA1c levels and IHF content were reduced after treatment in all three groups. However, HbA1c levels were lower in the liraglutide- and metformin-treated groups than in the Gliclazide-treated group, and reductions in IHF content were greater with liraglutide than with Gliclazide. Liraglutide and metformin treatments reduced weight and improved liver function. Changes in IHF content were positively correlated with reductions in serum alanine aminotransferase and triglyceride levels, as well as weight. At 24 weeks, reductions in IHF content were greater in subjects with weight loss >/=5%, changes in waistline /=2.5%, and HbA1c levels <6.5%. CONCLUSIONS: In T2DM patients with NAFLD, compared with liraglutide and metformin, Gliclazide resulted in less improvement in liver function, reductions in IHF content and HbA1c levels, and less weight loss; in addition, slightly better improvements were achieved with liraglutide than with metformin.
Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.[Pubmed:28017142]
Endocr Metab Immune Disord Drug Targets. 2016;16(4):230-234.
BACKGROUND: Insulin Autoimmune Syndrome (IAS) is a rare condition characterized by the combination of recurrent severely spontaneous hypoglycemia without evidence of exogenous insulin administration, high concentration of total serum insulin, and the presence of a high titer of insulin autoantibody (IAA). But now we describe a case with IAS caused by Gliclazide and hardly occuring hypoglycemia. CASE REPORT: A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high. He had no exogenous insulin administration history. Switching antidiabetic therapy from Gliclazide to acarbose and metformin, the patient's serum insulin level and IAA decreased gradually. Accordingly, the glycemic control improved and there was no episode of hypoglycemia. CONCLUSION: Hence, clinicians should pay more attention to type 2 diabetic patients treated with Gliclazide and detect their serum insulin concentration and IAA to exclude or diagnose IAS and perform the best therapeutic regimen to these patients.
Supramolecular Cocrystals of Gliclazide: Synthesis, Characterization and Evaluation.[Pubmed:28035627]
Pharm Res. 2017 Mar;34(3):552-563.
PURPOSE: To prepare the supramolecular cocrystals of Gliclazide (GL, a BCS class II drug molecule) via mechanochemical route, with the goal of improving physicochemical and biopharmaceutical properties. METHODS: Two cocrystals of GL with GRAS status coformers, sebacic acid (GL-SB; 1:1) and alpha-hydroxyacetic acid (GL-HA; 1:1) were screened out using liquid assisted grinding. The prepared cocrystals were characterized using thermal and analytical techniques followed by evaluation of antidiabetic activity and pharmacokinetic parameters. RESULTS: The generation of new, single and pure crystal forms was characterized by DSC and PXRD. The crystal structure determination from PXRD revealed the existence of both cocrystals in triclinic (P-1) crystal system. The hydrogen bonded network, determined by material studio was well supported by shifts in FTIR and SSNMR. Both the new solid forms displayed improved solubility, IDR, antidiabetic activity and pharmacokinetic parameters as compared to GL. CONCLUSIONS: The improvement in these physicochemical and biopharmaceutical properties corroborated the fact that the supramolecular cocrystallization may be useful in the development of pharmaceutical crystalline materials with interesting network and properties.
Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models.[Pubmed:27895517]
J Exp Pharmacol. 2016 Nov 17;8:69-76.
PURPOSE: Patients suffering from obesity-related diseases use multiple prescription drugs to control their condition, and it is therefore essential to determine the safety and efficacy of any combination. Gliclazide is one of the most commonly used drug of choice for treatment of type 2 diabetes, and curcumin is a widely used herbal supplement to counter obesity condition. The objective of this study was to investigate the effect of oral administration of curcumin on pharmacodynamics and pharmacokinetics of Gliclazide in rats and rabbits to further evaluate the safety and effectiveness of this combination. METHODS: Influence of curcumin on the activity of Gliclazide was determined by conducting single- and multiple-dose interaction studies in rats (normal and diabetic) and rabbits. Blood samples collected at predetermined time intervals from experimental animals were used for the estimation of glucose and insulin levels by using automated clinical chemistry analyzer and radioimmunoassay method, respectively. The insulin resistance and beta-cell function were determined by homeostasis model assessment. Additionally, serum Gliclazide levels in rabbits were analyzed by high-performance liquid chromatography. RESULTS: Gliclazide showed peak reduction in blood glucose levels at 2 and 8 hours in rats and at 3 hours in rabbits. This activity of Gliclazide was not altered by single-dose treatment with curcumin. However, in multiple-dose interaction studies, samples analyzed from all time points showed subtle but significantly greater reduction in percent blood glucose ranging from 23.38% to 42.36% in normal rats, 27.63% to 42.27% in diabetic rats, and 16.50% to 37.88% in rabbits. The pharmacokinetics of Gliclazide was not altered by single- or multiple-dose curcumin treatments in rabbits. CONCLUSION: The interaction of curcumin with Gliclazide up on multiple-dose treatment was pharmacodynamic in nature, indicating the need for periodic monitoring of glucose levels and dose adjustment as necessary when this combination is prescribed to obese patients.
